Meerut Reporter

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Lyme Disease Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Lyme Disease, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Lyme Disease Market

• The market size for Lyme Disease in the leading markets is expected to grow significantly by 2036.

• The United States accounted for the highest Lyme Disease market size in the 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.

• DelveInsight’s analysis indicates that the Lyme Disease market in the 7MM is expected to increase from approximately USD 3.7 billion in 2022 to nearly USD 5.9 billion by 2036, driven by increasing disease incidence, rising healthcare expenditure, and the anticipated launch of emerging therapies.

• According to the report, Lyme Disease is the most common vector-borne illness in North America and Europe, with the risk of infection influenced by the geographic distribution of Ixodes ticks, ecological factors, and human exposure patterns.

• According to the CDC, more than 89,000 cases of Lyme Disease were reported in the United States in 2023, with approximately 56.3% of cases occurring in men.

• According to the Infectious Agents Surveillance Report, the incidence rate of Lyme Disease in Japan was 0.008 per 100,000 population, while Hokkaido recorded the highest incidence rate at 0.069 per 100,000 population.

• DelveInsight’s analysis suggests that children aged 5–15 years and adults aged over 50 years remain among the most affected populations, reflecting the disease’s epidemiological burden across endemic regions.

• Leading Lyme Disease companies, such as Valneva, Pfizer, Tarsus Pharmaceuticals, Moderna, and others, are developing innovative prophylactic and therapeutic options expected to transform the Lyme Disease treatment landscape during the forecast period.

• The promising Lyme Disease therapies in clinical development include VLA15, TP-05, mRNA-1982, mRNA-1975, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/lyme-disease-ld-market

Key Factors Driving the Lyme Disease Market

Increasing Incidence of Tick-borne Infections: Climate change, expanding tick habitats, urbanization, changing land-use patterns, and increased outdoor recreational activities have contributed to a rising incidence of Lyme Disease across North America and Europe, creating a greater demand for preventive and therapeutic interventions.

Growing Need for Effective Preventive Strategies: Although antibiotic therapy remains effective during the early stages of Lyme Disease, there are currently no commercially available human vaccines. Increasing disease burden has accelerated research into preventive vaccines and novel prophylactic therapies that may significantly reduce future infection rates.

Advancement in Vaccine and Therapeutic Development: Several biotechnology and pharmaceutical companies are developing innovative vaccines and oral prophylactic agents designed to prevent Lyme Disease before infection occurs. These next-generation products have the potential to reshape disease prevention strategies across endemic regions.

Lyme Disease Competitive Landscape

Several Lyme Disease therapies are currently under clinical development, including VLA15 (Valneva and Pfizer), TP-05 (Tarsus Pharmaceuticals), mRNA-1982, and mRNA-1975 (Moderna).

These investigational candidates utilize diverse approaches, including multivalent outer surface protein A (OspA)-based vaccines, oral antiparasitic prophylaxis, and messenger RNA (mRNA) vaccine technology. These innovative strategies are expected to provide long-term protection against multiple Borrelia species while addressing the growing global burden of Lyme Disease.

Discover more about therapies set to grab major Lyme Disease market share @ Lyme Disease Treatment Landscape

Recent Developments in the Lyme Disease Market

• In November 2025, Valneva announced positive final immunogenicity and safety data from the Phase II VLA15-221 study evaluating its Lyme Disease vaccine candidate VLA15.

• In May 2025, Tarsus Pharmaceuticals announced plans to initiate a Phase II study evaluating TP-05, an investigational oral tablet for the prevention of Lyme Disease, in 2026.

• In September 2024, Valneva and Pfizer reported additional positive Phase II booster data supporting the continued clinical development of VLA15.

• In July 2024, Pfizer and Valneva announced that participants enrolled in the Phase III VALOR trial had completed the three-dose primary vaccination series of VLA15, with regulatory submissions to the US FDA and EMA anticipated following positive study results.

What is Lyme Disease?

Lyme Disease is a bacterial infection caused primarily by Borrelia burgdorferi and, less commonly, Borrelia mayonii, transmitted to humans through the bite of infected blacklegged ticks. The disease typically progresses through early localized, early disseminated, and late disseminated stages, with clinical manifestations ranging from erythema migrans and flu-like symptoms to neurological, cardiac, and musculoskeletal complications if left untreated. Early diagnosis and timely antibiotic therapy, including doxycycline or amoxicillin, remain the standard of care, while next-generation vaccines and prophylactic therapies are expected to significantly improve disease prevention and long-term management.

Lyme Disease Epidemiology Segmentation

The Lyme Disease epidemiology section provides insights into the historical and current Lyme Disease patient pool and forecasted trends for the leading markets. The Lyme Disease market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Incident Cases of Lyme Disease

• Gender-specific Incident Cases of Lyme Disease

• Age-specific Incident Cases of Lyme Disease

• Treatable Cases of Lyme Disease

Scope of the Lyme Disease Market Report

• Therapeutic Assessment: Lyme Disease current marketed and emerging therapies

• Lyme Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Lyme Disease Drugs and Market Outlook

• Key Companies: Valneva, Pfizer, Tarsus Pharmaceuticals, Moderna, and others

• Key Therapies: VLA15, TP-05, mRNA-1982, mRNA-1975, doxycycline, amoxicillin, cefuroxime axetil, azithromycin, ceftriaxone, and others

• Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, Lyme Disease Market Access and Reimbursement

To know more about Lyme Disease companies working in the treatment market, visit @ Lyme Disease Clinical Trials and Therapeutic Assessment

Table of Contents

• Lyme Disease Market Report Introduction

• Executive Summary for Lyme Disease

• Key Events

• Lyme Disease Market Overview at a Glance

• Emerging Therapies Analysis

• Market Share (%) Distribution of Lyme Disease by Therapies

• Epidemiology and Market Forecast Methodology

• Lyme Disease Background and Overview

• Clinical Manifestations

• Causes and Risk Factors

• Types of Lyme Disease

• Pathophysiology

• Diagnosis

• Diagnostic Algorithm

• Diagnostic Guidelines

• Treatment and Management

• Treatment Algorithm

• Treatment Guidelines

• Lyme Disease Epidemiology and Patient Population

• Country-Specific Patient Population of Lyme Disease

• Patient Journey

• Emerging Products

• Lyme Disease Market Outlook

• Conjoint Analysis

• Country-Wise Lyme Disease Market Analysis (2022–2036)

• Market Size of Lyme Disease by Therapies

• Market Access and Reimbursement of Therapies

• KOL Views

• SWOT Analysis

• Lyme Disease Unmet Needs

• Lyme Disease Appendix

• Lyme Disease Report Methodology

• DelveInsight Capabilities

• Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/